Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

NCT03737994 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Alectinib
DRUG: Brigatinib
DRUG: Carboplatin
DRUG: Ceritinib
DRUG: Cisplatin
DRUG: Crizotinib
DRUG: Ensartinib
DRUG: Lorlatinib
DRUG: Pemetrexed

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]